Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tapinarof 1% · 1 trial · 1 indication
Proportion of patients with treatment success (defined as a Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement from baseline at the end of treatment (Week 12; Study Day 84): Score of (0) Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may be present Score of (1) Almost Clear: No thickening; normal to pink coloration; no to minimal focal scaling Score of (2) Mild: Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling Score of (3) Moderate: Clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable erythema; moderate scaling Score of (4) Severe: Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions
| Arm | Type | Description |
|---|---|---|
| Test: Tapinarof Cream 1% | EXPERIMENTAL | Tapinarof Cream 1%, Apply a thin layer once daily to psoriatic affected areas for 84 days. |
| VTAMA® | ACTIVE_COMPARATOR | (Tapinarof) Cream 1%, Apply a thin layer once daily to psoriatic affected areas for 84 days. |
| Vehicle Product | PLACEBO_COMPARATOR | Vehicle of the Test Product, Cream, Apply a thin layer once daily to psoriatic affected areas for 84 days. |
| Name | Type | Description |
|---|---|---|
| Tapinarof Cream 1% | DRUG | Cream |
| VTAMA® | DRUG | Cream |
| Placebo | DRUG | Cream |
Inclusion Criteria: 1. Signed ICF indicating that the patient understands the purpose of, and procedures required for the study and is willing to participate in the study. 2. Males and non-pregnant, non-lactating females aged ≥18 at the time of signing the informed consent. 3. Patients with clinica...
Tapinarof 1% is a small molecule being developed for the treatment of plaque type psoriasis, a dermatological condition. It is currently in Phase 3 clinical development and is being studied as a topical cream formulation.
Tapinarof 1% is being developed by Teva Pharmaceutical Industries Limited, which is publicly traded under the ticker symbol TEVA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy for plaque psoriasis.
Tapinarof 1% is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 clinical trial has been completed to assess its effects in patients with plaque type psoriasis.
Tapinarof 1% has one completed Phase 3 clinical trial, identified as NCT06742957. This randomized, double-blind, placebo-controlled study enrolled 560 participants in the United States to compare Tapinarof Cream 1% to VTAMA (Tapinarof Cream 1%) in the treatment of plaque psoriasis.
Tapinarof 1% is being studied as a potential generic or alternative version of VTAMA (Tapinarof Cream 1%). The clinical trial NCT06742957 directly compares Tapinarof Cream 1% to VTAMA (Tapinarof Cream 1%) in patients with plaque psoriasis to evaluate their equivalence.